|
2 Companies |
|
2 Products |
|
2 Products |
|
1 Mechanism of Action |
|
0 Trials |
|
29 News |
|
- | deferasirox tablet for oral suspension / Generic mfg.
Biomarker, Enrollment change, Trial withdrawal: Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 4, 2024
P2, N=0, Withdrawn, Sponsor: Haukeland University Hospital
N=50 --> 0 | Terminated --> Withdrawn
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change, Trial completion date: Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis. (clinicaltrials.gov) - Apr 20, 2019
P2, N=62, Completed, Sponsor: Rennes University Hospital
N=50 --> 0 | Terminated --> Withdrawn Recruiting --> Completed | N=100 --> 62 | Trial completion date: Oct 2019 --> Dec 2018
- | Kineret (anakinra) / SOBI
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: THERA Study: Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study (clinicaltrials.gov) - Mar 12, 2019
P2, N=17, Terminated, Sponsor: Rennes University Hospital
Recruiting --> Completed | N=100 --> 62 | Trial completion date: Oct 2019 --> Dec 2018 N=56 --> 17 | Trial completion date: May 2019 --> Sep 2018 | Recruiting --> Terminated | Trial primary completion date: Feb 2019 --> Sep 2018; Poor recruitment
- | Phase classification: Iron Overload in Stem Cell Transplant Recipients (clinicaltrials.gov) - Mar 26, 2018
P, N=38, Completed, Sponsor: Boston Children
N=56 --> 17 | Trial completion date: May 2019 --> Sep 2018 | Recruiting --> Terminated | Trial primary completion date: Feb 2019 --> Sep 2018; Poor recruitment Phase classification: P=N/A --> P
- | Trial completion: HEMOCOEUR: Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis (clinicaltrials.gov) - Oct 20, 2017
P=N/A, N=66, Completed, Sponsor: Rennes University Hospital
Phase classification: P=N/A --> P Recruiting --> Completed
- | Kineret (anakinra) / SOBI
Trial primary completion date: THERA Study: Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study (clinicaltrials.gov) - Jul 5, 2017
P2, N=56, Recruiting, Sponsor: Rennes University Hospital
Recruiting --> Completed Trial primary completion date: Aug 2017 --> Feb 2019
- | Trial primary completion date: Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis. (clinicaltrials.gov) - May 31, 2017
P2, N=100, Recruiting, Sponsor: Rennes University Hospital
Trial primary completion date: Aug 2017 --> Feb 2019 Trial primary completion date: Apr 2017 --> Apr 2019
- deferasirox tablet for oral suspension / Generic mfg.
Biomarker, Trial termination, Trial primary completion date: Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome (clinicaltrials.gov) - Jan 23, 2017
P2, N=50, Terminated, Sponsor: Haukeland University Hospital
Trial primary completion date: Apr 2017 --> Apr 2019 Recruiting --> Terminated | Trial primary completion date: Mar 2014 --> Jan 2017; Failure to recruit patients with hemochromatosis to the Deferasirox arm
- Trial completion, Trial primary completion date: Mi-iron - Moderately Increased Iron - is Reducing Iron Overload Necessary? (clinicaltrials.gov) - Sep 27, 2016
P=N/A, N=100, Completed, Sponsor: Murdoch Childrens Research Institute
Recruiting --> Terminated | Trial primary completion date: Mar 2014 --> Jan 2017; Failure to recruit patients with hemochromatosis to the Deferasirox arm Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jul 2016
- Trial primary completion date: HEMOCOEUR: Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis (clinicaltrials.gov) - Jul 19, 2016
P=N/A, N=60, Recruiting, Sponsor: Rennes University Hospital
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jul 2016 Trial primary completion date: May 2016 --> Nov 2017
- | NN1213 / Novo Nordisk
Trial completion: Hemochromatosis and Iron Overload Screening Study (HEIRS) (clinicaltrials.gov) - Apr 12, 2016
P=N/A, N=0, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial primary completion date: May 2016 --> Nov 2017 No longer recruiting --> Completed
- Trial completion, Enrollment change: FEROS: Bone Status on Patients With Genetic Hemochromatosis: a 3 Years Descriptive and Evolutionary Study (clinicaltrials.gov) - May 27, 2015
P=N/A, N=100, Completed, Sponsor: Rennes University Hospital
No longer recruiting --> Completed Active, not recruiting --> Completed | N=150 --> 100
- Kineret (anakinra) / SOBI
Enrollment open, Trial initiation date, Trial primary completion date: THERA Study: Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study (clinicaltrials.gov) - Feb 19, 2015
P2, N=56, Recruiting, Sponsor: Rennes University Hospital
Active, not recruiting --> Completed | N=150 --> 100 Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> Feb 2015 | Trial primary completion date: Apr 2017 --> Aug 2017
- Enrollment open, Trial primary completion date: HEMOCOEUR: Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=60, Recruiting, Sponsor: Rennes University Hospital
Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> Feb 2015 | Trial primary completion date: Apr 2017 --> Aug 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2015 --> May 2016
- | Kineret (anakinra) / SOBI
New P2 trial: THERA Study: Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study (clinicaltrials.gov) - Oct 15, 2014
P2, N=56, Not yet recruiting, Sponsor: Rennes University Hospital
- Trial initiation date: HEMOCOEUR: Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=60, Not yet recruiting, Sponsor: Rennes University Hospital
Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2015 --> May 2016 Initiation date: May 2014 --> Sep 2014
- Trial completion: HEPFER-Evaluation of a New Phenotypic Biological Marker in Genetic Type 1 Hemochromatosis (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=31, Completed, Sponsor: Rennes University Hospital
Initiation date: May 2014 --> Sep 2014 Recruiting --> Completed
- Clinical: HEMOCOEUR: Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis (clinicaltrials.gov) - Mar 26, 2014
P=N/A, N=60, Not yet recruiting, Sponsor: Rennes University Hospital
- Trial initiation date: Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis. (clinicaltrials.gov) - Feb 17, 2014
P2, N=100, Recruiting, Sponsor: Rennes University Hospital
Recruiting --> Completed Initiation date: Oct 2013 --> Feb 2014
- Enrollment open: Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis. (clinicaltrials.gov) - Nov 24, 2013
P2, N=100, Recruiting, Sponsor: Rennes University Hospital
Initiation date: Oct 2013 --> Feb 2014 Not yet recruiting --> Recruiting
- | New P2 trial: Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis. (clinicaltrials.gov) - Sep 22, 2013
P2, N=100, Recruiting, Sponsor: Rennes University Hospital
- | deferasirox tablet for oral suspension / Generic mfg.
Biomarker, New P2 trial: Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome (clinicaltrials.gov) - Jul 2, 2013
P2, N=50, Recruiting, Sponsor: Haukeland University Hospital
- Enrollment closed: FEROS: Bone Status on Patients With Genetic Hemochromatosis: a 3 Years Descriptive and Evolutionary Study (clinicaltrials.gov) - May 27, 2013
P=N/A, N=150, Active, not recruiting, Sponsor: Rennes University Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Enrollment open: HEPFER-Evaluation of a New Phenotypic Biological Marker in Genetic Type 1 Hemochromatosis (clinicaltrials.gov) - Feb 18, 2013
P=N/A, N=35, Recruiting, Sponsor: Rennes University Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||||| deferiprone / Generic mfg.
Trial completion: Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients (clinicaltrials.gov) - Nov 15, 2012
P3, N=95, Completed, Sponsor: Lipomed
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- hydroxyurea / Generic mfg.
Trial initiation date: Stroke With Transfusions Changing to Hydroxyurea (clinicaltrials.gov) - Aug 14, 2012
P3, N=134, Terminated, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Initiation date: Aug 2005 --> Oct 2006
- | deferiprone / Generic mfg.
Trial completion, Combination therapy: Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients (clinicaltrials.gov) - Dec 8, 2011
P2, N=24, Completed, Sponsor: Lipomed
Initiation date: Aug 2005 --> Oct 2006 Active, not recruiting --> Completed